Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity

Blood

Volumn 127, Issue 1, 2016, Pages 132-138

  Yu, Xiaojie ^a,b   Menard, Melissa ^b,c   Prechl, József ^d   Bhakta, Varsha ^a,e   Sheffield, William P ^a,e   Lazarus, Alan H ^a,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIIB ANTIBODY; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; ALBUMINOID; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; BASOPHIL; BINDING AFFINITY; BODY TEMPERATURE; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING; DRUG TARGETING; FEMALE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE THROMBOCYTOPENIA; IN VITRO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTOPENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL CULTURE; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ALBUMINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MACROPHAGES; MICE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 84955482400     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-664656     Document Type: Article

References (51)

1. Michel M, Lee K, Piette JC, et al. Platelet autoantibodies and lupus-associated thrombocytopenia. Br J Haematol. 2002;119(2): 354-358.
2. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007; 44(4, suppl 5): S3-S11.
3. Warner M, Kelton JG. Laboratory investigation of immune thrombocytopenia. J Clin Pathol. 1997; 50(1): 5-12.
4. McCrae K. Immune thrombocytopenia: No longer 'idiopathic'. Cleve Clin J Med. 2011;78(6): 358-373.
5. Hou M, Stockelberg D, Kutti J, Wadenvik H. Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): Evidence for at least two different IgG antibodies. Br J Haematol. 1997;98(1): 64-67.
6. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1): 34-47.
7. Fleit HB, Wright SD, Unkeless JC. Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci USA. 1982;79(10): 3275-3279.
8. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med. 1986;314(19): 1236-1239.
9. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol. 2000; 37(3): 261-266.
10. Psaila B, Bussel JB. Fc receptors in immune thrombocytopenias: A target for immunomodulation? J Clin Invest. 2008;118(8): 2677-2681.
11. Nakar CT, Bussel JB. 3G8 and GMA161, anti FcgRIII inhibitory monoclonal antibodies in the treatment of chronic refractory ITP (summary of 2 pilot studies) [abstract]. Blood. 2009;114(22). Abstract 2404.
12. Khodoun MV, Kucuk ZY, Strait RT, et al. Rapid desensitization of mice with anti-FcgRIIb/FcgRIII mAb safely prevents IgG-mediated anaphylaxis. J Allergy Clin Immunol. 2013;132(6): 1375-1387.
13. Iwamoto H, Matsubara T, Nakazato Y, Namba K, Takeda Y. Decreased expression of CD200R3 on mouse basophils as a novel marker for IgG1- mediated anaphylaxis. Immun Inflamm Dis. 2015; 3(3): 280-288.
14. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25: 21-50.
15. Flaherty MM, MacLachlan TK, Troutt M, et al. Nonclinical evaluation of GMA161-an antihuman CD16 (FcgRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. Toxicol Sci. 2012;125(1): 299-309.
16. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6): 868-876.
17. Jevsevar S, Kusterle M, Kenig M. PEGylation of antibody fragments for half-life extension. Methods Mol Biol. 2012;901: 233-246.
18. Yu X, Baruah K, Harvey DJ, et al. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc. 2013;135(26): 9723-9732.
19. Yu X, Menard M, Seabright G, Crispin M, Lazarus AH. A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects. Transfusion. 2015;55(6, pt 2): 1501-1511.
20. Verma A, Ngundi MM, Meade BD, De Pascalis R, Elkins KL, Burns DL. Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin Vaccine Immunol. 2009;16(10): 1405-1412.
21. Nei Y, Obata-Ninomiya K, Tsutsui H, et al. GATA-1 regulates the generation and function of basophils. Proc Natl Acad Sci USA. 2013;110(46): 18620-18625.
22. Lantz CS, Min B, Tsai M, Chatterjea D, Dranoff G, Galli SJ. IL-3 is required for increases in blood basophils in nematode infection in mice and can enhance IgE-dependent IL-4 production by basophils in vitro. Lab Invest. 2008;88(11): 1134-1142.
23. Hill DA, Siracusa MC, Abt MC, et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. Nat Med. 2012;18(4): 538-546.
24. Evans L, Hughes M, Waters J, et al. The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2010;73(2): 113-124.
25. Nelson AL. Antibody fragments: Hope and hype. MAbs. 2010;2(1): 77-83.
26. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: Principles and clinical application. Clin Dev Immunol. 2012;2012: 980250.
27. Beeken WL, Volwiler W, Goldsworthy PD, et al. Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest. 1962;41: 1312-1333.
28. Dixon FJ, Maurer PH, Deichmiller MP. Half-lives of homologous serum albumins in several species. Proc Soc Exp Biol Med. 1953;83(2): 287-288.
29. Stevens DK, Eyre RJ, Bull RJ. Adduction of hemoglobin and albumin in vivo by metabolites of trichloroethylene, trichloroacetate, and dichloroacetate in rats and mice. Fundam Appl Toxicol. 1992;19(3): 336-342.
30. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: Studies in experimental immune thrombocytopenia. Blood. 2001;98(4): 1095-1099.
31. Nieswandt B, Echtenacher B, Wachs FP, et al. Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood. 1999;94(2): 684-693.
32. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005; 310(5753): 1510-1512.
33. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat Rev Immunol. 2013; 13(3): 176-189.
34. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apheresis Sci. 2003;28(3): 249-255.
35. Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by crosslinking human immunoglobulin G with a highaffinity monoclonal antibody. Br J Haematol. 2006;135(1): 97-100.
36. Llewelyn M, Cohen J. Superantigens: Microbial agents that corrupt immunity. Lancet Infect Dis. 2002;2(3): 156-162.
37. Strait RT, Morris SC, Yang M, Qu XW, Finkelman FD. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol. 2002;109(4): 658-668.
38. Tsujimura Y, Obata K, Mukai K, et al. Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity. 2008;28(4): 581-589.
39. Cassard L, Jönsson F, Arnaud S, Daëron M. Fcg receptors inhibit mouse and human basophil activation. J Immunol. 2012;189(6): 2995-3006.
40. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs. 2011;3(5): 415-416.
41. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3): 214-221.
42. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21): 1451-1458.
43. Smith BJ, Popplewell A, Athwal D, et al. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem. 2001;12(5): 750-756.
44. Olafsen T. Fc engineering: Serum half-life modulation through FcRn binding. Methods Mol Biol. 2012;907: 537-556.
45. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9): 715-725.
46. Gradishar WJ. Albumin-bound paclitaxel: A nextgeneration taxane. Expert Opin Pharmacother. 2006;7(8): 1041-1053.
47. Trujillo JM, Nuffer W. Albiglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48(11): 1494-1501.
48. Dich J, Nielsen K. Metabolism and distribution of I-labelled albumin in the pig. Can J Comp Med Vet Sci. 1963;27(11): 269-273.
49. Sell S. The catabolism of alpha1-fetoprotein and albumin in rats bearing Morris hepatoma 7777. Cancer Res. 1974;34(7): 1608-1611.
50. Campbell RM, Cuthbertson DP, Mackie W, McFarlane AS, Phillipson AT, Sudsaneh S. Passage of plasma albumin into the intestine of the sheep. J Physiol. 1961;158(1): 113-131.
51. Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F. Broad requirement for terminal sialic acid residues and FcgRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur J Immunol. 2014; 44(5): 1444-1453.